Combination treatment for chronic hepatitis C: What is the role of ribavirin?

Fundamental and Clinical Pharmacology

Volumn 14, Issue 4, 2000, Pages 321-325

  Souvignet, Claude ^a   Zarski, Jean Pierre ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Academic review; Antiviral; Chronic hepatitis; Hepatitis C virus; Immunomodulator; Pharmacology; Ribavirin; Therapeutic use

Indexed keywords

ALPHA2B INTERFERON; CD4 ANTIGEN; CYTOKINE; GUANOSINE DERIVATIVE; RIBAVIRIN;

ANTIVIRAL ACTIVITY; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HELPER CELL; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0033816721     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2000.tb00412.x     Document Type: Review

References (28)

1. Standards of treatment in chronic hepatitis C
2. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
3. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
4. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
5. Randomised double-blind, placebo controlled trial of interferon α-2b with without ribavirin for chronic hepatitis C
6. Hepatite C: Depistage et traitement. Conference de consensus
7. The clinical pharmacology of ribavirin
8. Ribavirin interferon α-2b in chronic hepatitis C: Assessment of possible pharmacokinetic pharmacodynamic interactions
9. Broad spectrum activity of virazole 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
10. Antiviral drugs
11. Respiratory syncytial virus (RSV) disease prospects for its control
12. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin
13. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon
14. Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients
15. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
16. Effects of the ribavirin-interferon α combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients
17. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis
18. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents
19. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response
20. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile
21. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
22. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
23. Regulation of the signal transduction program by drugs